Keflin Neutral

What it is used for

KEFLIN is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. Culture and susceptibility studies should be performed. Therapy may be instituted before results of susceptibility studies are obtained (See notes under Microbiology). Respiratory tract infections caused by S. pneumoniae, staphylococci (penicillinase and non-penicillinase-producing), group A beta-haemolytic streptococci, Klebsiella, and H. influenzae. Skin and soft-tissue infections, including peritonitis, caused by staphylococci (penicillinase and non-penicillinase-producing), group A beta-haemolytic streptococci, E. coli, Pr. mirabilis, and Klebsiella. Genito-urinary tract infections caused by E. coli, Pr. mirabilis and Klebsiella. Septicaemia, including endocarditis, caused by S. pneumoniae, staphylococci (penicillinase and non-penicillinase-producing), group A beta-haemolytic streptococci, S. viridans; E. coli, Pr. mirabilis, and Klebsiella. Bone and joint infections caused by staphylococci (penicillinase and non-penicillinase-producing). Prophylactically in vaginal hysterectomy, head and neck surgery, insertion of prosthetic heart valves, and prosthetic arthroplasty. Cephalothin is not recommended for G.I. procedures or other sites where anaerobic organisms such as bacteroides tend to prevail. Dosage is required pre-, intra- and post- operatively (i.e. perioperatively – See DOSAGE and ADMINISTRATION). If signs of postoperative infection develop, specimens should be cultured to identify the causative organism so that appropriate therapy can be instituted. NOTE: If the susceptibility tests show that the causative organism is resistant to KEFLIN, other appropriate antibiotic therapy should be instituted.